[PDF][PDF] Three neglected numbers in the CBC: The RDW, MPV, and NRBC count
JE May, MB Marques, VVB Reddy, R Gangaraju - Cleve Clin J Med, 2019 - ccjm.org
The complete blood cell count (CBC) is one of the most frequently ordered laboratory tests,
but some values included in the test may be overlooked. This brief review discusses 3 …
but some values included in the test may be overlooked. This brief review discusses 3 …
[HTML][HTML] Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura
…, CH Kim, NK Kocher, L Zheng, R Gangaraju… - …, 2019 - ncbi.nlm.nih.gov
Immune-mediated thrombotic thrombocytopenic purpura is characterized by severe
thrombocytopenia and microangiopathic hemolytic anemia. It is primarily caused by immunoglobin G …
thrombocytopenia and microangiopathic hemolytic anemia. It is primarily caused by immunoglobin G …
Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia
Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV) and essential
thrombocythemia (ET). The pathophysiology of thrombosis in these disorders remains …
thrombocythemia (ET). The pathophysiology of thrombosis in these disorders remains …
Race, rituximab, and relapse in TTP
…, HV Upreti, A Liu, MY Lim, R Gangaraju… - Blood, The Journal …, 2022 - ashpublications.org
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring
episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black …
episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black …
[HTML][HTML] Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from …
…, G Spectre, MY Lim, A Gahagan, R Gangaraju… - Journal of Thrombosis …, 2021 - Elsevier
Background Cancer patients are increasingly prescribed direct oral anticoagulants (DOACs)
and targeted anticancer therapies, but limited data are available on the outcomes during …
and targeted anticancer therapies, but limited data are available on the outcomes during …
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
…, B Guillory, LA Williams, R Gangaraju… - Blood …, 2019 - ashpublications.org
Immune thrombotic thrombocytopenic purpura (iTTP) is primarily caused by immunoglobulin
G (IgG)–type autoantibodies that bind and inhibit plasma ADAMTS13 activity and/or …
G (IgG)–type autoantibodies that bind and inhibit plasma ADAMTS13 activity and/or …
Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis
…, M Horvathova, R Gangaraju… - American Journal of …, 2023 - Wiley Online Library
Obstructive sleep apnea (OSA) causes intermittent hypoxia during sleep. Hypoxia predictably
initiates an increase in the blood hemoglobin concentration (Hb); yet in our analysis of 527 …
initiates an increase in the blood hemoglobin concentration (Hb); yet in our analysis of 527 …
Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia
Background Coagulopathy and associated bleeding and deep vein thrombosis (DVT) are
major causes of morbidity and mortality in patients with acute leukemia. The underlying …
major causes of morbidity and mortality in patients with acute leukemia. The underlying …
Regulation of erythropoiesis after normoxic return from chronic sustained and intermittent hypoxia
J Song, K Sundar, R Gangaraju… - Journal of Applied …, 2017 - journals.physiology.org
Hypoxia increases erythropoiesis mediated by hypoxia-inducible transcription factors (HIF),
which regulate erythropoietin transcription. Neocytolysis is a physiological mechanism that …
which regulate erythropoietin transcription. Neocytolysis is a physiological mechanism that …
Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model
R Gangaraju, Y Chen, L Hageman, J Wu… - Blood …, 2021 - ashpublications.org
Allogeneic blood or marrow transplant (BMT) recipients are at risk for venous
thromboembolism (VTE) because of high-intensity therapeutic exposures, comorbidities, and a …
thromboembolism (VTE) because of high-intensity therapeutic exposures, comorbidities, and a …